youtube_live
Q3 2026 earnings • released • EPS beat +4.33% • Revenue beat +16.04%
See resultschevron_right
ZYME:NASDAQ
Zymeworks Inc
$29.07
arrow_downward
-7.60%(-2.39) 1D
$29.07
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 11, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZYME...
Open
$31.80
High
$31.94
Low
$28.92
Mkt. cap
2.05B
Avg. vol.
1.37M
Volume
0.00
52-wk high
$31.96
52-wk low
$18.20
EPS
-$2.01
Beta
1.32
Shares outstanding
69.03M
No. of employees
231
Open
$31.80
High
$31.94
Low
$28.92
Mkt. cap
2.05B
Avg. vol.
1.37M
Volume
0.00
52-wk high
$31.96
52-wk low
$18.20
EPS
-$2.01
Beta
1.32
Shares outstanding
69.03M
No. of employees
231
News stories
From web sources and news partners
TradingView
·
8 hours ago
ZYME: Zanidatamab royalties fund a flexible mix of R&D, buybacks and opportunistic deals
Investing.com
·
9 hours ago
Zymeworks at stifel 2026 healthcare conference: royalties, deals and growth
GuruFocus
·
13 hours ago
ZYME Maintains Buy Rating -- Price Target Raised to $44.00 by Citigroup
GuruFocus
·
1 day ago
ZYME Maintains by TD Cowen -- Price Target Raised to $39.00
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees231
Founded2003
HeadquartersMiddletown, Delaware, United States
SectorHealth Care
IndustryBiotechnology
Websitezymeworks.com